Axelgaard Manufacturing Co. Revenue and Competitors

Fallbrook, CA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Axelgaard Manufacturing Co.'s estimated annual revenue is currently $12M per year.(i)
  • Axelgaard Manufacturing Co.'s estimated revenue per employee is $251,000

Employee Data

  • Axelgaard Manufacturing Co. has 48 Employees.(i)
  • Axelgaard Manufacturing Co. grew their employee count by -2% last year.

Axelgaard Manufacturing Co.'s People

NameTitleEmail/Phone
1
Director SalesReveal Email/Phone
2
Regulatory Affairs ManagerReveal Email/Phone
3
Quality Control ManagerReveal Email/Phone
4
R&D Engineering Manager and Sales EngineerReveal Email/Phone
5
HR ManagerReveal Email/Phone
6
mechanical R&D engineerReveal Email/Phone
7
PresidentReveal Email/Phone
8
R&D Executive AssistantReveal Email/Phone
9
Information Technology AdministratorReveal Email/Phone
10
Production SupervisorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Axelgaard Manufacturing Co.?

Founded in 1985, Axelgaard Manufacturing Co., Ltd. (AMC) has grown to become the premier manufacturer of neurostimulation electrodes. Our primary brand is our patented PALS® Neurostimulation Electrodes. We are dedicated to providing the highest quality products incorporating the latest in materials and technology. Our customer service department provides the best customer service in the industry. As a result of this dedication to the correct application of technology, and our excellent customer service, the PALS Electrodes have become the world wide number one brand neurostimulation electrode. AMC was founded to offer clinicians an alternative to the poor clinical performance of neurostimulation electrodes existing in 1985. Co-founder Dr. Jens Axelgaard had been working for several years as the Director of Spinal Engineering Research at Rancho Los Amigos Hospital. It was during his tenure at Rancho Los Amigos that he designed and developed the PALS Electrodes to fit his clinical needs. Dr. Axelgaard is world renowned for his development of the Lateral Electrical Surface Stimulation (LESS) treatment for Idiopathic Adolescent Scoliosis and has authored or co-authored more than 30 professional papers. This clinical experience became the backbone of how and why our PALS became a reality. Our patented PALS were unique in 1985 and are still unique today. They were the first electrodes to totally integrate the use of a pigtail leadwire, conductive fabric and self adhesive gel. Since the introduction of PALS, AMC has received patents on various applications using differing concepts of fabric electrodes, creative ways of enhancing the performance of conductive carbon film, and improved adhesive gel technology. The results provide increased ease of use for patients and clinicians, as well as more comfortable and effective treatments.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$12M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Axelgaard Manufacturing Co. News

2022-04-17 - Global Rapid Self-Healing Gel Market To Be Driven By Increasing ...

The major players in the market are Advanced Medical Solutions Group Plc, Axelgaard Manufacturing Co. Ltd., Cardinal Health Inc. (NYSE: CAH), Hydromer Inc.,...

2022-04-17 - Hydrogel Dressing Market Scenario & Prominent Key Players ...

It helps corporation leaders make higher choices when foreign money change records are ... Johnson & Johnson, Procyon Corp., and Axelgaard Manufacturing Co.

2022-04-06 - Hydrogel Market Share Will Continue To Expand Steadily Through ...

– Procyon Corp. – Axelgaard Manufacturing Co. Ltd. LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.8M50-4%N/A
#2
$14.6M645%N/A
#3
$7.5M787%N/A
#4
$15M1780%N/A